These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 38991681)
1. Background incidence rates of health outcomes of interest for COVID-19 vaccine safety monitoring in a US population: a claims database analysis. Banga S; Khromava A; Serradell L; Chabanon AL; Pan C; Estevez I; Schilsky S; Kreisberg H BMJ Open; 2024 Jul; 14(7):e083947. PubMed ID: 38991681 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial. Akova M; Unal S Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccine safety in Scotland - background rates of adverse events of special interest. Cullen LA; Grange Z; Antal K; Waugh L; Alsina MS; Gibbons CL; MacDonald LE; Robertson C; Cameron JC; Stockton D; O'Leary MC Public Health; 2023 Nov; 224():1-7. PubMed ID: 37688806 [TBL] [Abstract][Full Text] [Related]
4. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020. Moll K; Lufkin B; Fingar KR; Ke Zhou C; Tworkoski E; Shi C; Hobbi S; Hu M; Sheng M; McCarty J; Shangguan S; Burrell T; Chillarige Y; Beers J; Saunders-Hastings P; Muthuri S; Edwards K; Black S; Kelman J; Reich C; Amend KL; Djibo DA; Beachler D; Ogilvie RP; Secora A; McMahill-Walraven CN; Seeger JD; Lloyd P; Thompson D; Dimova R; MaCurdy T; Obidi J; Anderson S; Forshee R; Wong HL; Shoaibi A Vaccine; 2023 Jan; 41(2):333-353. PubMed ID: 36404170 [TBL] [Abstract][Full Text] [Related]
5. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults. Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110 [TBL] [Abstract][Full Text] [Related]
6. The Risk of Optic Neuritis following mRNA Coronavirus Disease 2019 Vaccination Compared to Coronavirus Disease 2019 Infection and Other Vaccinations. Shukla P; Sharma N; Shaia JK; Cohen DA; Singh RP; Talcott KE Ophthalmology; 2024 Sep; 131(9):1076-1082. PubMed ID: 38408705 [TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. Safety of Ancestral Monovalent BNT162b2, mRNA-1273, and NVX-CoV2373 COVID-19 Vaccines in US Children Aged 6 Months to 17 Years. Hu M; Shoaibi A; Feng Y; Lloyd PC; Wong HL; Smith ER; Amend KL; Kline A; Beachler DC; Gruber JF; Mitra M; Seeger JD; Harris C; Secora A; Obidi J; Wang J; Song J; McMahill-Walraven CN; Reich C; McEvoy R; Do R; Chillarige Y; Clifford R; Cooper DD; Forshee RA; Anderson SA JAMA Netw Open; 2024 Apr; 7(4):e248192. PubMed ID: 38656578 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study. Ogilvie RP; Layton JB; Lloyd PC; Jiao Y; Djibo DA; Wong HL; Gruber JF; Parambi R; Deng J; Miller M; Song J; Weatherby LB; Peetluk L; Lo AC; Matuska K; Wernecke M; Bui CL; Clarke TC; Cho S; Bell EJ; Yang G; Amend KL; Forshee RA; Anderson SA; McMahill-Walraven CN; Chillarige Y; Anthony MS; Seeger JD; Shoaibi A BMC Pediatr; 2024 Apr; 24(1):276. PubMed ID: 38671379 [TBL] [Abstract][Full Text] [Related]
10. Impact of Long SARS-CoV-2 Omicron Infection on the Health Care Burden: Comparative Case-Control Study Between Omicron and Pre-Omicron Waves. Valdivieso-Martinez B; Lopez-Sanchez V; Sauri I; Diaz J; Calderon JM; Gas-Lopez ME; Lidon L; Philibert J; Lopez-Hontangas JL; Navarro D; Cuenca L; Forner MJ; Redon J JMIR Public Health Surveill; 2024 Sep; 10():e53580. PubMed ID: 39226091 [TBL] [Abstract][Full Text] [Related]
11. Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study. Xu S; Sy LS; Hong V; Holmquist KJ; Qian L; Farrington P; Bruxvoort KJ; Klein NP; Fireman B; Han B; Lewin BJ JMIR Public Health Surveill; 2024 Jun; 10():e53807. PubMed ID: 38916940 [TBL] [Abstract][Full Text] [Related]
12. Sex and gender differences in adverse events following influenza and COVID-19 vaccination. Yin A; Wang N; Shea PJ; Rosser EN; Kuo H; Shapiro JR; Fenstermacher KZJ; Pekosz A; Rothman RE; Klein SL; Morgan R Biol Sex Differ; 2024 Jun; 15(1):50. PubMed ID: 38890702 [TBL] [Abstract][Full Text] [Related]
13. Background incidence rates of hospitalisations and emergency department visits for thromboembolic and coagulation disorders in Ontario, Canada for COVID-19 vaccine safety assessment: a population-based retrospective observational study. Nasreen S; Calzavara AJ; Sundaram ME; MacDonald SE; Righolt CH; Pai M; Field TS; Zhou LW; Wilson SE; Kwong JC BMJ Open; 2021 Dec; 11(12):e052019. PubMed ID: 34921078 [TBL] [Abstract][Full Text] [Related]
14. Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras. Xie Y; Choi T; Al-Aly Z N Engl J Med; 2024 Aug; 391(6):515-525. PubMed ID: 39018527 [TBL] [Abstract][Full Text] [Related]
15. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. Li X; Ostropolets A; Makadia R; Shoaibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard MA; Ryan PB; Hripcsak G; Prieto-Alhambra D BMJ; 2021 Jun; 373():n1435. PubMed ID: 35727911 [TBL] [Abstract][Full Text] [Related]
16. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759 [TBL] [Abstract][Full Text] [Related]
17. Use of Immunization Information Systems in Ascertainment of COVID-19 Vaccinations for Claims-Based Vaccine Safety and Effectiveness Studies. Schneider KL; Bell EJ; Zhou CK; Yang G; Lloyd P; Clarke TC; Wilkinson M; Myers EE; Amend KL; Seeger JD; Chillarige Y; Forshee RA; Shoaibi A; Anderson SA; Wong HL JAMA Netw Open; 2023 May; 6(5):e2313512. PubMed ID: 37191962 [TBL] [Abstract][Full Text] [Related]
18. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417 [TBL] [Abstract][Full Text] [Related]
19. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602 [TBL] [Abstract][Full Text] [Related]
20. Pregnancy and infant outcomes following SARS-CoV-2 infection in pregnancy during delta variant predominance - Surveillance for Emerging Threats to Pregnant People and Infants. Reeves EL; Neelam V; Carlson JM; Olsen EO; Fox CJ; Woodworth KR; Nestoridi E; Mobley E; Montero Castro S; Dzimira P; Sokale A; Sizemore L; Hall AJ; Ellington S; Cohn A; Gilboa SM; Tong VT Am J Obstet Gynecol MFM; 2024 Feb; 6(2):101265. PubMed ID: 38135220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]